Trial Profile
Long term safety and efficacy of Ustekinumab in refractory Crohn's disease patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2018
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 08 Jan 2018 Results of a study evaluating long term safety and efficacy and identifying the predictive factors of ustekinumab failure free persistence published in the Alimentary Pharmacology and Therapeutics
- 08 Dec 2017 New trial record
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week